Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 2
2014 3
2015 2
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, Pierga JY, de la Motte Rouge T, Sabatier R, Dubot C, Frenel JS, Ferrero JM, Ladoire S, Levy C, Mouret-Reynier MA, Lortholary A, Grenier J, Chakiba C, Stefani L, Plaza JE, Clatot F, Teixeira L, D'Hondt V, Vegas H, Derbel O, Garnier-Tixidre C, Canon JL, Pistilli B, André F, Arnould L, Pradines A, Bièche I, Callens C, Lemonnier J, Berger F, Delaloge S; PADA-1 investigators. Bidard FC, et al. Lancet Oncol. 2022 Nov;23(11):1367-1377. doi: 10.1016/S1470-2045(22)00555-1. Epub 2022 Sep 29. Lancet Oncol. 2022. PMID: 36183733 Clinical Trial.
Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.
Berger F, Marce M, Delaloge S, Hardy-Bessard AC, Bachelot T, Bièche I, Pradines A, De La Motte Rouge T, Canon JL, André F, Arnould L, Clatot F, Lemonnier J, Marques S, Bidard FC; PADA-1 investigators. Berger F, et al. BMJ Open. 2022 Mar 3;12(3):e055821. doi: 10.1136/bmjopen-2021-055821. BMJ Open. 2022. PMID: 35241469 Free PMC article. Clinical Trial.
What to expect from immediate salvage hysterectomy following concomitant chemoradiation and image-guided adaptive brachytherapy in locally advanced cervical cancer.
Castelnau-Marchand P, Chargari C, Bouaita R, Dumas I, Farha G, Kamsu-Kom L, Rivin Del Campo E, Martinetti F, Morice P, Haie-Meder C, Mazeron R. Castelnau-Marchand P, et al. Among authors: bouaita r. Cancer Radiother. 2015 Dec;19(8):710-7. doi: 10.1016/j.canrad.2015.05.025. Epub 2015 Oct 21. Cancer Radiother. 2015. PMID: 26508320
Breast radiotherapy (RT) using tangential fields (TgF): a prospective evaluation of the dose distribution in the sentinel lymph node (SLN) area as determined intraoperatively by clip placement.
Belkacemi Y, Bigorie V, Pan Q, Bouaita R, Pigneur F, Itti E, Badaoui H, Assaf E, Caillet P, Calitchi E, Bosc R. Belkacemi Y, et al. Among authors: bouaita r. Ann Surg Oncol. 2014 Nov;21(12):3758-65. doi: 10.1245/s10434-014-3966-1. Epub 2014 Aug 6. Ann Surg Oncol. 2014. PMID: 25096388 Free PMC article.